Christopher Gibson
Co-Founder and CEO, Recursion Pharmaceuticals
Christopher Gibson is co-founder and CEO of Recursion Pharmaceuticals, a clinical-stage biopharma company leveraging the latest in automation, artificial intelligence, biology, and chemistry to discover new medicines at scale. In 2013, he completed his PhD at the University of Utah, where he trained with Recursion co-founder Dean Li, then took a leave of absence from medical school to start and grow the company. Gibson is a board member of CureHHT, a patient advocacy group for Hereditary Hemorrhagic Telangiectasia, and a member of the Rare and Undiagnosed Network Advisory Board. Holding undergraduate degrees in bioengineering and managerial studies, he completed an entrepreneurship course at Stanford Graduate School of Business.
Previously
The algorithms used in machine learning and other forms of artificial intelligence are remarkable in the speed at which they can analyze vast quantities of data to identify pa...
Once inventions work their way into widespread use –- the Internet and the cell phone, the X-ray machine and the CT scanner –- we stop thinking about them as novelties, and st...